Dublin, Feb. 02, 2017 -- Research and Markets has announced the addition of the "Subcutaneous Self-Administration Markets to 2024" report to their offering.
Because of the ongoing need for repeat dosing posed by chronic diseases, these indications represent significant drug volume and revenue opportunities, while simultaneously challenging the industry to develop products that meet the unique needs of the non-professional caregiver.
For drugs designed to be administered by the patient, therapy-specific packaging is improving adherence and treatment outcomes. In the area of delivery, reusable injection devices designed to accept prefilled syringes or drug cartridges are improving ease-of-use and increasing the alternative device share of the growing self-injection market. This report examines in detail the drugs, devices, therapeutics and markets that are set to drive the market for subcutaneous self-administration into the next decade.
Subcutaneous Self-Administration Markets to 2024 - What You Will Learn
- Provides detailed analysis of self-administered subcutaneous drug products, drug delivery and device strategies, and product development factors
- Assesses key markets, market dynamics and market demographics
- Analyzes therapeutic demand drivers and evaluates SC drug products in nine key therapeutic segments
- Provides market data and forecasts to 2024
- Profiles market sector participants, their product development activities, business strategies, and corporate alliances and affiliations
- Assesses the importance of alliances and partnerships on self-administered subcutaneous drug product commercialization
- Evaluates the impact of economic, technology, and regulatory factors
Key Topics Covered:
1. Executive Summary
2. Subcutaneous Self-Administration - Why it's Growing
- The Evolving Drug Pipeline
- Device and Packaging Technology Advances
- Shifting Patient Demographics
- Healthcare Economics
- Demand Drivers
- Innovation in Prefilled Device Designs
- Therapeutic Targets and Treatment
- Competitive Landscape
- Risk Factors
3. Subcutaneous Delivery Device Design Factors
- Ergonomics and Ease of Use
- Safety Features
- Needle Insertion Depth
- Dose Inspection/Injection Confirmation
- Lyophilized Drugs/Reconstitution
- High Viscosity Drugs
- High Volume Drugs
4. Subcutaneously Delivered Drugs - Delivery Device Strategies
- Handheld Devices
- Autoinjectors
- Pen Injectors
- Prefilled Syringes
- Other Handheld Devices
- Wearable Devices
- Patch Pumps
- Large Volume Wearable Devices
5. Subcutaneous Self-Administration
- Therapeutic Sector Product Analysis & Forecasts
- Anticoagulants
- Antivirals
- Autoimmune Diseases
- Diabetes
- Hematopoietics
- Hormone Replacement
- Neurology
- Osteoporosis
- Reproductive Health
6. Market Factors
- Regulatory Issues
- DTC Marketing
- Patient Education
7. Company Profiles
For more information about this report visit http://www.researchandmarkets.com/research/bn5bk2/subcutaneous
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Drug Delivery


OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Washington Post Publisher Will Lewis Steps Down After Layoffs
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 



